<DOC>
	<DOCNO>NCT02234843</DOCNO>
	<brief_summary>The purpose study evaluate comparative efficacy safety rivaroxaban standard care child acute venous thromboembolism .</brief_summary>
	<brief_title>EINSTEIN Junior Phase III : Oral Rivaroxaban Children With Venous Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Children age 6 month &lt; 18 year confirm venous thromboembolism receive initial treatment therapeutic dosage UFH ( unfractionated Heparin ) , LMWH ( low molecular weight heparin ) fondaparinux require anticoagulant therapy least 90 day Active bleed bleed risk contraindicate anticoagulant therapy An estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m*2 Hepatic disease associate either : coagulopathy lead clinically relevant bleeding risk , ALT &gt; 5x upper level normal ( ULN ) total bilirubin &gt; 2x ULN direct bilirubin &gt; 20 % total Platelet count &lt; 50 x 10*9/L Sustained uncontrolled hypertension define &gt; 95th age percentile Life expectancy &lt; 3 month Concomitant use strong inhibitor cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) Pglycoprotein ( Pgp ) , include limited human immunodeficiency virus protease inhibitor follow azole antimycotic agent : ketoconazole , itraconazole , voriconazole , posaconazole , use systemically Concomitant use strong inducer CYP3A4 , include limited rifampicin , rifabutin , phenobarbital , phenytoin carbamazepine Childbearing potential without proper contraceptive measure , pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
</DOC>